Vera Therapeutics Files 8-K
Ticker: VERA · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, regulatory-disclosure
TL;DR
Vera Therapeutics filed an 8-K, likely with regulatory updates.
AI Summary
On October 2, 2024, Vera Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Vera Therapeutics is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification without specific material events disclosed.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- October 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 8000 Marina Boulevard, Suite 120 (address) — Principal executive offices
- Brisbane, California (location) — Principal executive offices location
- 94005 (zip_code) — Principal executive offices zip code
- (650) 770-0077 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Vera Therapeutics, Inc.?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 2, 2024.
In which state is Vera Therapeutics, Inc. incorporated?
Vera Therapeutics, Inc. is incorporated in Delaware.
What is the address of Vera Therapeutics, Inc.'s principal executive offices?
The address is 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005.
What is the telephone number for Vera Therapeutics, Inc.?
The telephone number is (650) 770-0077.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2024-10-02 09:01:59
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
Filing Documents
- d802938d8k.htm (8-K) — 27KB
- d802938dex991.htm (EX-99.1) — 17KB
- d802938dex992.htm (EX-99.2) — 49KB
- g802938ex99_2p10g1.jpg (GRAPHIC) — 217KB
- g802938ex99_2p11g1.jpg (GRAPHIC) — 344KB
- g802938ex99_2p12g1.jpg (GRAPHIC) — 373KB
- g802938ex99_2p13g1.jpg (GRAPHIC) — 257KB
- g802938ex99_2p14g1.jpg (GRAPHIC) — 180KB
- g802938ex99_2p15g1.jpg (GRAPHIC) — 372KB
- g802938ex99_2p16g1.jpg (GRAPHIC) — 263KB
- g802938ex99_2p17g1.jpg (GRAPHIC) — 239KB
- g802938ex99_2p18g1.jpg (GRAPHIC) — 118KB
- g802938ex99_2p19g1.jpg (GRAPHIC) — 300KB
- g802938ex99_2p1g1.jpg (GRAPHIC) — 134KB
- g802938ex99_2p20g1.jpg (GRAPHIC) — 301KB
- g802938ex99_2p21g1.jpg (GRAPHIC) — 131KB
- g802938ex99_2p22g1.jpg (GRAPHIC) — 218KB
- g802938ex99_2p23g1.jpg (GRAPHIC) — 268KB
- g802938ex99_2p24g1.jpg (GRAPHIC) — 312KB
- g802938ex99_2p25g1.jpg (GRAPHIC) — 199KB
- g802938ex99_2p26g1.jpg (GRAPHIC) — 388KB
- g802938ex99_2p27g1.jpg (GRAPHIC) — 335KB
- g802938ex99_2p28g1.jpg (GRAPHIC) — 178KB
- g802938ex99_2p29g1.jpg (GRAPHIC) — 250KB
- g802938ex99_2p2g1.jpg (GRAPHIC) — 606KB
- g802938ex99_2p30g1.jpg (GRAPHIC) — 225KB
- g802938ex99_2p31g1.jpg (GRAPHIC) — 360KB
- g802938ex99_2p32g1.jpg (GRAPHIC) — 290KB
- g802938ex99_2p33g1.jpg (GRAPHIC) — 442KB
- g802938ex99_2p34g1.jpg (GRAPHIC) — 333KB
- g802938ex99_2p35g1.jpg (GRAPHIC) — 303KB
- g802938ex99_2p36g1.jpg (GRAPHIC) — 225KB
- g802938ex99_2p37g1.jpg (GRAPHIC) — 227KB
- g802938ex99_2p38g1.jpg (GRAPHIC) — 571KB
- g802938ex99_2p39g1.jpg (GRAPHIC) — 216KB
- g802938ex99_2p3g1.jpg (GRAPHIC) — 216KB
- g802938ex99_2p40g1.jpg (GRAPHIC) — 225KB
- g802938ex99_2p41g1.jpg (GRAPHIC) — 178KB
- g802938ex99_2p4g1.jpg (GRAPHIC) — 405KB
- g802938ex99_2p5g1.jpg (GRAPHIC) — 362KB
- g802938ex99_2p6g1.jpg (GRAPHIC) — 303KB
- g802938ex99_2p7g1.jpg (GRAPHIC) — 302KB
- g802938ex99_2p8g1.jpg (GRAPHIC) — 183KB
- g802938ex99_2p9g1.jpg (GRAPHIC) — 219KB
- 0001193125-24-230760.txt ( ) — 16177KB
- vera-20241002.xsd (EX-101.SCH) — 3KB
- vera-20241002_lab.xml (EX-101.LAB) — 18KB
- vera-20241002_pre.xml (EX-101.PRE) — 11KB
- d802938d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Vera Therapeutics, Inc., dated October 2, 2024. 99.2 Slide presentation entitled "R&D Day". 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: October 2, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer